Trial Profile
A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Antiandrogens; LHRH receptor agonists; LHRH receptor antagonists
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PEACE2
- Sponsors UNICANCER
- 05 Oct 2021 Planned End Date changed from 1 Dec 2032 to 1 Jul 2041.
- 05 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 trial design presented at the 46th European Society for Medical Oncology Congress